AlphaStocks
7.4
Consider Buy

Illumina, Inc. (ILMN)

As of Sep 20, 2026, Illumina, Inc. (ILMN) scores 7.4/10 on AlphaStocks' five-model composite, #9 of 168 Health Care stocks. At $240, ILMN trades 66% above its model fair value of $144.

Health Care / Life Sciences Tools & Services

S&P MidCap 400

$239.53

Above average across most dimensions. A solid candidate.

Consider Buy

Score based on 5 of 5 models — high confidence

Data as of Sep 20, 2026

#9out of 168 in Health Care

Is ILLUMINA, INC. a Good Investment in 2026?

ILLUMINA, INC. (ILMN) scores 7.4 out of 10 on AlphaStocks' composite model, earning a Consider Buy rating. The Piotroski model rates ILLUMINA, INC. as Strong (7/9). However, the Greenblatt Magic Formula model rates it Caution — Earnings yield 2.7% · ROC 33%. ILLUMINA, INC. currently trades 66% above its estimated fair value of $144. ILLUMINA, INC. ranks #9 out of 168 stocks in the Health Care sector.

This summary is algorithmically generated and is not financial advice.

Key Metrics

P/E44.0ROE10.9Market Cap37B

Estimated Fair Value

$144.1266% above

Trading above estimated fair value. P/e of 44x implies high growth expectations. eps growth of -41% may not justify the premium.

Model-based estimate, not a price target.

5-Model Analysis

Each model evaluates this stock from a different angle. Combined, they form the composite score above.

Piotroski

Strong

7/9

Buffett

Attractive

Business quality & competitive moat

Graham

Caution

Significantly above fair value

Lynch

Neutral

PEG 1.5 · Fast Grower

Greenblatt

Caution

Earnings yield 2.7% · ROC 33%

Frequently Asked Questions

Is ILLUMINA, INC. (ILMN) a good investment?
As of Sep 20, 2026, Illumina, Inc. (ILMN) scores 7.4/10 on AlphaStocks' five-model composite, #9 of 168 Health Care stocks. At $240, ILMN trades 66% above its model fair value of $144. That score is above average across most investment dimensions.
What is ILLUMINA, INC.'s Piotroski F-Score?
ILLUMINA, INC.'s Piotroski F-Score status is Strong. The raw score is 7/9. The Piotroski F-Score evaluates financial health using 9 fundamental signals including profitability, leverage, and operating efficiency.
Is ILMN overvalued or undervalued?
Based on AlphaStocks' model-based fair value estimate of $144, ILMN appears overvalued. The stock currently trades 66% above its estimated fair value. Trading above estimated fair value. P/e of 44x implies high growth expectations. eps growth of -41% may not justify the premium.
How does ILMN compare to other Health Care stocks?
ILLUMINA, INC. ranks #9 out of 168 stocks in the Health Care sector, placing it in the top 5% of its sector by composite score. This is a strong position relative to sector peers.
What do investment models say about ILMN?
AlphaStocks evaluates ILMN using five proven investment models. Piotroski: Strong; Buffett: Attractive; Graham: Caution; Lynch: Neutral; Greenblatt Magic Formula: Caution. These models are combined into a single composite score of 7.4/10.

Similar Stocks

BIOAZTAA

Compare ILMN with

BIO vs ILMNAZTA vs ILMNA vs ILMNILMN vs VAL

Scores are algorithm-generated research tools, not investment recommendations. Past performance does not guarantee future results. Always do your own due diligence. Full disclaimer